A study described a gene editing therapy in transgenic mice, homozygous for the human LMNA c.1824 C>T allele, that recapitulates HGPS symptoms, using retro-orbital injection of split-intein dual-AAV9 to deliver ABEmax at postnatal day 14 [122]. The gene discussed is LMNA; the disease is Hutchinson-Gilford progeria syndrome.